Pharmaceutical stocks demonstrated strong resilience today, with Dr Reddy's Labs leading gains at 7.8% intraday and reaching a day high of ₹1,313 per share on NSE. According to reports from Upstox, Cipla shares rose 4.7% intraday, while Piramal Pharma, Mankind Pharma, and Glenmark Pharmaceuticals also posted gains between 3% and 6%. This performance contrasted sharply with the broader market sell-off, as NIFTY50 and SENSEX declined amid investor caution. The latest developments show Piramal Pharma climbing more than 7% with record trading volumes, while IRM Energy surged over 15% on record volume of 3 crore shares.
The pharmaceutical sector's outperformance was attributed to its defensive characteristics, as reported by Upstox. The pharma sector is considered essential regardless of economic conditions, with sales and earnings remaining stable during economic slowdowns or recessions. Consumers typically cut back on luxury goods but continue to prioritize healthcare services, providing the sector with consistent demand. This defensive nature has helped pharma stocks maintain their appeal during periods of market uncertainty. The sector is projected for strong growth driven by domestic demand and expanding export markets, with the pharmaceutical sector expected to reach $120-$130 billion by 2030, fueled by innovation, generics, and global demand.
According to Upstox reports, Dr Reddy's shares rebounded sharply from last week's fall as investors closely track the company's drug approval progress. The company is awaiting approval for its weight-loss drug semaglutide in the Brazilian and Canada markets. However, challenges emerged as the Brazilian authority rejected Dr Reddy's application for the semaglutide drug due to further technical requirements, while Apotex Inc. received approval in the Canadian market ahead of Dr Reddy's Labs. Despite these setbacks, the stock showed strong intraday recovery. Piramal Pharma's strong trading activity was driven by its scheduled announcement of audited financial results for the quarter and fiscal year ended March 31, 2026, on April 28.
Piramal Pharma Limited saw exceptional trading activity with total traded volume on NSE surpassing 3.10 crore shares by 11:34 AM, marking its highest single-day volume since March 2025. This momentum builds ahead of its scheduled announcement of audited financial results for the quarter and fiscal year ended March 31, 2026, on April 28. IRM Energy also witnessed record trading volumes with over 3 crore shares traded by 11:30 AM, as the company operates within India's dynamic energy sector navigating increased demand and grid constraints. The high volume trading indicates strong investor interest separate from the market's overall mood, with both stocks showing company-specific strength amid broader market decline.
The pharmaceutical sector's outperformance was evident in year-to-date comparisons, as reported by Upstox. The NIFTY Pharma index has gained nearly 1% compared to an over 7% fall in the benchmark NIFTY50 and SENSEX index. This divergence highlights the defensive characteristics of the pharmaceutical sector, which continues to attract investor interest even during broader market volatility. The sector's resilience was supported by weak returns in broader markets and consistent sector performance in recent months, with analysts overwhelmingly rating Piramal Pharma a 'Strong Buy' with an average 12-month target of ₹200-₹228 INR, suggesting over 30% potential upside.
